{"id":65981,"date":"2026-05-22T21:06:25","date_gmt":"2026-05-22T13:06:25","guid":{"rendered":"https:\/\/flcube.com\/?p=65981"},"modified":"2026-05-22T21:06:27","modified_gmt":"2026-05-22T13:06:27","slug":"yangtze-river-pharma-secures-nmpa-approval-for-fazamorexant-next-generation-dora-for-insomnia-treatment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65981","title":{"rendered":"Yangtze River Pharma Secures NMPA Approval for Fazamorexant \u2013 Next-Generation DORA for Insomnia Treatment"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Yangtze River Pharmaceutical Group (YRPG)<\/strong> announced that China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> has granted <strong>marketing approval<\/strong> for <strong>fazamorexant<\/strong>, a <strong>Category 1 innovative dual orexin receptor antagonist (DORA)<\/strong> indicated for the <strong>treatment of adult insomnia<\/strong> characterized by difficulty falling asleep and\/or maintaining sleep.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Full marketing approval, Category 1 innovative drug<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Fazamorexant (oral)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Treatment of adult patients with insomnia (sleep onset and\/or maintenance difficulties)<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>22 May 2026<\/td><\/tr><tr><td><strong>Next Steps<\/strong><\/td><td>Commercial launch preparation and market access negotiations<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Dual orexin receptor antagonist (DORA)<\/li>\n\n\n\n<li><strong>Target:<\/strong> Orexin receptors OX1 and OX2 in the brain&#8217;s wake-promoting system<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> Demonstrates rapid onset of action with sustained efficacy over long-term use<\/li>\n\n\n\n<li><strong>Intellectual Property:<\/strong> Developed by YRPG with proprietary formulation and clinical data package<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-evidence-phase-iii-trials\" class=\"wp-block-heading\">Clinical Evidence \u2013 Phase III Trials<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Result (Fazamorexant)<\/th><th>Comparator (Other DORAs)<\/th><th>Relative Benefit<\/th><\/tr><\/thead><tbody><tr><td><strong>Time to Sleep Onset<\/strong><\/td><td>Significantly reduced<\/td><td>Published clinical data<\/td><td><strong>Numerically superior<\/strong><\/td><\/tr><tr><td><strong>Nighttime Awakenings<\/strong><\/td><td>Markedly improved<\/td><td>Published clinical data<\/td><td><strong>Numerically superior<\/strong><\/td><\/tr><tr><td><strong>Sleep Efficiency<\/strong><\/td><td>Enhanced metrics<\/td><td>Published clinical data<\/td><td><strong>Numerically superior<\/strong><\/td><\/tr><tr><td><strong>Long-term Efficacy<\/strong><\/td><td>Benefits maintained at 6 months<\/td><td>Limited long-term data available<\/td><td><strong>Sustained therapeutic effect<\/strong><\/td><\/tr><tr><td><strong>Safety<\/strong><\/td><td>Discontinuation rate: 0.6%; No rebound insomnia or withdrawal symptoms<\/td><td>Variable across class<\/td><td><strong>Favorable safety profile<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The pivotal Phase III studies demonstrated significant improvements in both objective sleep parameters measured by polysomnography (PSG) and subjective sleep indicators recorded in patient sleep diaries after just 14 days of treatment.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China Insomnia Landscape:<\/strong> Affecting approximately 15% of China&#8217;s adult population, representing a substantial market opportunity for effective, well-tolerated treatments<\/li>\n\n\n\n<li><strong>Competitive Edge:<\/strong> Fazamorexant&#8217;s combination of rapid onset, sustained efficacy, and favorable safety profile differentiates it from existing insomnia therapies<\/li>\n\n\n\n<li><strong>Commercial Strategy:<\/strong> YRPG plans to leverage its established distribution network to ensure broad market access across urban and rural healthcare settings<\/li>\n\n\n\n<li><strong>Global Potential:<\/strong> The robust clinical data package may support future regulatory submissions in international markets seeking next-generation insomnia treatments<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding commercial expectations for fazamorexant. Actual results may differ due to risks including market adoption, competitive dynamics, and reimbursement decisions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Yangtze River Pharmaceutical Group (YRPG) announced that China&#8217;s National Medical Products Administration (NMPA) has granted&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[15],"class_list":["post-65981","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Yangtze River Pharma Secures NMPA Approval for Fazamorexant \u2013 Next-Generation DORA for Insomnia Treatment - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Yangtze River Pharmaceutical Group (YRPG) announced that China&#039;s National Medical Products Administration (NMPA) has granted marketing approval for fazamorexant, a Category 1 innovative dual orexin receptor antagonist (DORA) indicated for the treatment of adult insomnia characterized by difficulty falling asleep and\/or maintaining sleep.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65981\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Yangtze River Pharma Secures NMPA Approval for Fazamorexant \u2013 Next-Generation DORA for Insomnia Treatment\" \/>\n<meta property=\"og:description\" content=\"Yangtze River Pharmaceutical Group (YRPG) announced that China&#039;s National Medical Products Administration (NMPA) has granted marketing approval for fazamorexant, a Category 1 innovative dual orexin receptor antagonist (DORA) indicated for the treatment of adult insomnia characterized by difficulty falling asleep and\/or maintaining sleep.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65981\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-22T13:06:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-22T13:06:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65981#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65981\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Yangtze River Pharma Secures NMPA Approval for Fazamorexant \u2013 Next-Generation DORA for Insomnia Treatment\",\"datePublished\":\"2026-05-22T13:06:25+00:00\",\"dateModified\":\"2026-05-22T13:06:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65981\"},\"wordCount\":364,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65981#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65981\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65981\",\"name\":\"Yangtze River Pharma Secures NMPA Approval for Fazamorexant \u2013 Next-Generation DORA for Insomnia Treatment - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-22T13:06:25+00:00\",\"dateModified\":\"2026-05-22T13:06:27+00:00\",\"description\":\"Yangtze River Pharmaceutical Group (YRPG) announced that China's National Medical Products Administration (NMPA) has granted marketing approval for fazamorexant, a Category 1 innovative dual orexin receptor antagonist (DORA) indicated for the treatment of adult insomnia characterized by difficulty falling asleep and\\\/or maintaining sleep.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65981#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65981\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65981#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Yangtze River Pharma Secures NMPA Approval for Fazamorexant \u2013 Next-Generation DORA for Insomnia Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Yangtze River Pharma Secures NMPA Approval for Fazamorexant \u2013 Next-Generation DORA for Insomnia Treatment - Insight, China&#039;s Pharmaceutical Industry","description":"Yangtze River Pharmaceutical Group (YRPG) announced that China's National Medical Products Administration (NMPA) has granted marketing approval for fazamorexant, a Category 1 innovative dual orexin receptor antagonist (DORA) indicated for the treatment of adult insomnia characterized by difficulty falling asleep and\/or maintaining sleep.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65981","og_locale":"en_US","og_type":"article","og_title":"Yangtze River Pharma Secures NMPA Approval for Fazamorexant \u2013 Next-Generation DORA for Insomnia Treatment","og_description":"Yangtze River Pharmaceutical Group (YRPG) announced that China's National Medical Products Administration (NMPA) has granted marketing approval for fazamorexant, a Category 1 innovative dual orexin receptor antagonist (DORA) indicated for the treatment of adult insomnia characterized by difficulty falling asleep and\/or maintaining sleep.","og_url":"https:\/\/flcube.com\/?p=65981","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-22T13:06:25+00:00","article_modified_time":"2026-05-22T13:06:27+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65981#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65981"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Yangtze River Pharma Secures NMPA Approval for Fazamorexant \u2013 Next-Generation DORA for Insomnia Treatment","datePublished":"2026-05-22T13:06:25+00:00","dateModified":"2026-05-22T13:06:27+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65981"},"wordCount":364,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65981#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65981","url":"https:\/\/flcube.com\/?p=65981","name":"Yangtze River Pharma Secures NMPA Approval for Fazamorexant \u2013 Next-Generation DORA for Insomnia Treatment - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-22T13:06:25+00:00","dateModified":"2026-05-22T13:06:27+00:00","description":"Yangtze River Pharmaceutical Group (YRPG) announced that China's National Medical Products Administration (NMPA) has granted marketing approval for fazamorexant, a Category 1 innovative dual orexin receptor antagonist (DORA) indicated for the treatment of adult insomnia characterized by difficulty falling asleep and\/or maintaining sleep.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65981#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65981"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65981#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Yangtze River Pharma Secures NMPA Approval for Fazamorexant \u2013 Next-Generation DORA for Insomnia Treatment"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65981","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65981"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65981\/revisions"}],"predecessor-version":[{"id":65983,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65981\/revisions\/65983"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65981"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65981"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65981"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}